【作者】 刘珊珊；

【导师】 张瑾熔；

【作者基本信息】 新疆医科大学 ， 肿瘤学， 2010， 硕士

【摘要】 目的:探讨食管鳞状细胞癌(ESCC)癌组织中X线修复交叉互补基因(1XRCC1)、切除修复交叉互补基因1(ERCC1)的蛋白表达与放射治疗疗效及预后的相关性。方法:采用免疫组织化学SP法检测了59例治疗前ESCC组织和23例癌旁组织标本中XRCC1、ERCC1的蛋白表达,结合临床病理特征和随访数据进行分析。结果:XRCC1、ERCC1蛋白主要表达于细胞核,两者表达无明显相关性。XRCC1蛋白在ESCC组织和癌旁组织中的阳性表达率分别为52.5%和13.0%,P=0.001。ERCC1蛋白在ESCC组织和癌旁组织中的阳性表达率分别为33.9%和65.2%,P=0.010。XRCC1蛋白在汉族组和少数民族组阳性表达率分别为72.2%和43.9%,P=0.045。ERCC1蛋白在无淋巴结转移组和有淋巴结转移组阳性表达率分别为48.3%和20.0%,P=0.022。XRCC1表达阴性组的近期放疗有效率为92.9%,较阳性组的80.6%略有升高,P=0.323。ERCC1表达阳性组和阴性组患者的中位生存期分别为13.2个月(95%CI:10.1～16.3)、21.4个月(95%CI:19.1～23.7),P=0.001。多因素分析显示ERCC1表达、病变长度与患者的生存期密切相关,是独立的预后因素(P=0.001、0.037)。结论:XRCC1、ERCC1的蛋白表达情况可能在食管癌的发生中起一定作用。ERCC1的蛋白表达与食管癌的淋巴结转移及放射治疗预后密切相关,其阳性表达是预后不良的标志。更多还原

【Abstract】 Objective: To analyze the relationship between the protein expressions of X-ray repair cross-complementing 1, excision repair cross complementing 1 and the effect of radiotherapy and prognosis in esophageal squamous cell carcinoma (ESCC). Methods: The protein expression of XRCC1 and ERCC1 in 59 samples of ESCC tissues and 23 adjacent tissues were examined using SP immunohistochemical staining and were analyzed according to the clinic pathologic features and follow-up data. Results: XRCC1 and ERCC1 protein were expressed in the nucleus of tumor cells in ESCC. There were no correlation between the expression of XRCC1 and ERCC1. The positive expression rate of XRCC1 protein in ESCC and adjacent tissues were 52.5% and 13.0%, respectively(P=0.001). The positive expression rate of ERCC1 protein in ESCC and adjacent tissues were 33.9%and 65.2%, respectively(P=0.010). The positive expression rate of XRCC1 protein in the group of Han nation and the group of minority were 72.2% and 43.9%, respectively (P=0.045). The positive expression rate of ERCC1 protein in the negative lymphnode group and positive lymphnode group were 48.3% and 20.0%, respectively (P=0.022). The short-term effect of radiotherapy in the negative-XRCC1 group (92.9%)was higher than that in the positive-XRCC1 group(80.6%), P=0.323. The median survival period and 95 confidence interval in the group of positive expression of ERCC1 and the group of negative expression of ERCC1 were 13.2 months, 10.1～16.3 months, 21.4 months and 19.1～23.7 months, respectively(P=0.001). In multivariate analysis, the expression of ERCC1 and the tumor length were closely correlated with over all survival and were the independent prognostic factor(sP=0.001, 0.037). Conclusion: The protein expression of XRCC1 and ERCC1 may contribute to the risk of developing ESCC. The expression of ERCC1 is closely correlated with the lymphnode metastasis and effect of radiotherapy, and its positive expression is an unfavorable factor for prognosis of ESCC.更多还原